Boniva for treatment and prevention of postmenopausal osteoporosis

Boniva (ibandronate sodium) is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women. It works by increasing bone mineral density and reducing the risk of spine fractures associated with osteoporosis.

Boniva is specifically approved for the treatment and prevention of osteoporosis in postmenopausal women. It is intended to improve bone strength and lower the chance of vertebral fractures in this population.

ibandronate sodium

Boniva belongs to the bisphosphonate class of drugs that work by inhibiting the activity of osteoclasts, the cells responsible for bone breakdown. This action slows bone loss and helps maintain or increase bone density, thereby helping to prevent fractures.

Dosing Options

• One 150 mg tablet once monthly on the same date each month.
• Or one 2.5 mg tablet once daily.

Administration Instructions

• Swallow the tablet whole with 6 to 8 ounces of plain water only.
• Take Boniva at least 60 minutes before the first food, beverage (other than water), or medication of the day.
• Remain upright (standing or sitting) for at least 60 minutes after taking to reduce esophageal irritation risk.
• Do not eat, drink (except water), or take other medications for 60 minutes post-dose.
• Avoid mineral waters with high calcium content as they may affect absorption.
• Do not chew or suck the tablet to prevent oropharyngeal irritation.

Missed Dose Instructions for Monthly Dose

• If more than 7 days until next scheduled dose, take the missed 150 mg tablet the morning after remembering, then resume original schedule.
• If less than 7 days until next scheduled dose, skip the missed dose and take the next one on the usual day.

Special Populations

• Not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min).
• No dose adjustment needed for mild/moderate renal impairment, elderly, or hepatic impairment.
• Calcium and vitamin D supplementation should be used if dietary intake is insufficient.

• Abnormalities of the esophagus that delay esophageal emptying, such as stricture or achalasia
• Inability to stand or sit upright for at least 60 minutes
• Hypocalcemia
• Known hypersensitivity to Boniva or any of its ingredients

Gastrointestinal Risks

Boniva can cause severe irritation of the upper gastrointestinal tract, including esophagitis, ulcers, and erosions, sometimes leading to bleeding or esophageal stricture or perforation. Patients should follow dosing instructions carefully and discontinue Boniva if symptoms like difficulty swallowing, painful swallowing, or new/worsening heartburn occur.

Hypocalcemia

Low blood calcium levels should be corrected before starting therapy to prevent worsening hypocalcemia during treatment.

Severe Musculoskeletal Pain

Some patients experience severe bone, joint, or muscle pain. Consider discontinuing Boniva if such symptoms develop.

Osteonecrosis of the Jaw (ONJ)

Cases of jaw osteonecrosis have been reported, especially in cancer patients but also in those treated for osteoporosis. Risk factors include dental procedures, cancer, chemotherapy, corticosteroids, and pre-existing dental disease. Dental surgery may worsen ONJ. Management should be individualized.

Renal Impairment

Boniva is not recommended for severe renal impairment (creatinine clearance <30 mL/min).

Common Adverse Reactions (≥5%)

• Back pain
• Dyspepsia (indigestion)
• Pain in extremity
• Diarrhea
• Headache
• Myalgia (muscle pain)

Other Adverse Events Observed in Clinical Trials

• Asthenia
• Allergic reactions including rash
• Gastrointestinal complaints: vomiting, gastritis, abdominal pain, nausea, constipation
• Respiratory infections: bronchitis, upper respiratory tract infections, pneumonia
• Musculoskeletal disorders: joint disorder, arthritis, muscle cramps
• Nervous system: dizziness, vertigo, nerve root lesion
• Influenza-like illness (more common with monthly dosing)
• Ocular inflammation such as uveitis or scleritis has been reported postmarketing

Boniva absorption is reduced by intake of calcium-containing foods, antacids, vitamins, and other oral medications if taken too soon after Boniva. It is critical to take Boniva at least 60 minutes before these substances to ensure proper absorption and effect.